PMID- 27685907
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20181202
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 21
IP  - 4
DP  - 2016 Jul-Aug
TI  - Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system 
      in human gastric cancer cells.
PG  - 867-873
AB  - PURPOSE: Cetuximab is a monoclonal antibody against epidermal growth factor 
      receptor (EGFR) and is approved for clinical use in combination with chemotherapy 
      in patients affected by colorectal cancer (CRC), non small cell lung cancer 
      (NSCLC), and head and neck cancer. Compared with these cancers, gastric cancer is 
      relatively resistant to cetuximab and its regulatory mechanism is still unclear. 
      METHODS: In this study, we assessed whether the ubiquitin- proteasome pathway is 
      involved in regulating cetuximab-induced cells apoptosis in MGC803 and BGC823 
      gastric cancer cell lines. RESULTS: The casitas B lineage lymphoma-b (Cbl-b), a 
      kind of E3 ubiquitin ligase, was involved in this process. Specific silenced 
      Cbl-b expression increased the expression of EGFR. CONCLUSIONS: Our findings lead 
      to a better understanding of the mechanism of cetuximab action, and suggests that 
      Cbl-b increases the sensitivity of cetuximab in gastric cancer cells.
FAU - Yu, Ping
AU  - Yu P
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang, China.
FAU - Fan, Yibo
AU  - Fan Y
FAU - Qu, Xiujuan
AU  - Qu X
FAU - Zhang, Jingdong
AU  - Zhang J
FAU - Song, Na
AU  - Song N
FAU - Liu, Jing
AU  - Liu J
FAU - Liu, Yunpeng
AU  - Liu Y
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Ubiquitin)
RN  - EC 2.3.2.27 (CBLB protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-cbl)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*metabolism
MH  - Antibodies, Monoclonal/pharmacology
MH  - Antineoplastic Agents/pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Cetuximab/*pharmacology
MH  - Drug Resistance, Neoplasm/physiology
MH  - ErbB Receptors/metabolism
MH  - Humans
MH  - Proteasome Endopeptidase Complex/*metabolism
MH  - Proto-Oncogene Proteins c-cbl/*metabolism
MH  - Stomach Neoplasms/*drug therapy/*metabolism
MH  - Ubiquitin/*metabolism
EDAT- 2016/09/30 06:00
MHDA- 2017/03/04 06:00
CRDT- 2016/09/30 06:00
PHST- 2016/09/30 06:00 [entrez]
PHST- 2016/09/30 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
PST - ppublish
SO  - J BUON. 2016 Jul-Aug;21(4):867-873.